Skip to main content
Clinical Trials/NCT07138677
NCT07138677CompletedNot Applicable

The Safty and Efficacy of Mild Cognitiive Impairment Network Guided Transcranial Magnetic Stimulations for Patients With Early Alzheimer's Disease (SENS-eAD): A Randomized, Double-blind Trial

Anhui Medical University1 site in 1 country40 target enrollmentStarted: July 20, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)

Study Overview

Brief Summary

Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients

Detailed Description

All patients undergo a series of medical assessments that include physical examination and routine laboratory studies before and after repetitive transcranial magnetic stimulation (rTMS) treatment. Upon meeting the inclusion criteria and providing informed consent, each participant will complete a series of cognitive assessments and rTMS treatments at the First Affiliated Hospital of AnHui medical university. Stratified block randomization will be used to assign participants to different intervention groups. Stratification is based on Mini-Mental State Examination (MMSE) scores (<24 vs. ≥24), and randomization will be conducted using variable block sizes of 4 or 6.

For each participant, the investigators will compute their persoanlized dorsal prefrontal targets by using their own resting-state functional MRI data and a predefined MCI network. They will then be randomly assigned to receive real or sham rTMS treatment for two weeks. The sham stimulations will be delivered by a sham coil. All the experiment procedures are the same between groups except the coil.

With a statistical power of 0.8, an effect size of 0.96, a significance level of 0.05, and a 5% expected dropout rate, the final sample size is 20 participants per group. In this double-blind study, patients and clinical raters are masked to the allocated conditions. Only one investigator responsible for group allocation has access to the randomization list.

Each participant will be treated for 14 days by rTMS. Before the rTMS treatment, a trained investigator will perform a series of cognitive assessments and neuropsychological tests. The ADAS-Cog is the primary outcome. Other tasks and questionnaires include cognition (including MoCA, MMSE, DS, Stroop test, BNT-30, VFT, CDT, JLOT. Form H, HVOT), memory (CAVLT, LMT), emotion (HAMA-17,HAMD-14), behavioral and psychological symptoms (NPI), and treatment tolerability. All the tests will be conducted within two days. The participants undergo a multi-modal MRI scan and an electroencephalogram (EEG) examination.

The participants also undergo the ADAS-cog, a battery of neuropsychological tests, multi-modal MRI, and EEG examinations. participants will be instructed to focus their answers on the past 14 days.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
45 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
  • •MMSE score 18-
  • •CDR score 0.5-
  • •On stable treatment with IAChE or memantine for at least 6 months.
  • •Literate in Han Chinese.

Exclusion Criteria

  • •Recevied rTMS treatment in the past 3 months.
  • •Depression or other psychiatric disorders.
  • •History of head injury, stroke, epilepsy or other neurologic disease.
  • •Organic brain defects on T1 or T2 images.
  • •History of unexplained loss of consciousness.
  • •Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
  • •Family history of medication refractory epilepsy.
  • •History of substance abuse within the last 6 months.

Arms & Interventions

MCI real group

Experimental

Stimulation delivered by a real coil through MagStim Rapid2 and guided by BrainSight navigation system.

Intervention: transcranial magnetic stimulation (Other)

MCI sham group

Sham Comparator

Stimulation delivered by a sham coil through MagStim Rapid2 and guided by BrainSight navigation system.

Intervention: transcranial magnetic stimulation (Other)

Outcomes

Primary Outcomes

Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)

Time Frame: Baseline and 2 weeks

The changes in Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog) will constitute the major research outcome measure used to assess response to transcranial magnetic stimulation (TMS). The ADAS-COG scale tests orientation, language, structure, use of ideas, immediate recall of words and word re-recognition, and consists of 11 questions out of a possible 70 points, with the higher the score the more cognitively impaired.

Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)

Time Frame: Baseline and 2 weeks

The changes in Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog) will constitute the major research outcome measure used to assess response to transcranial magnetic stimulation (TMS). The ADAS-COG scale tests orientation, language, structure, use of ideas, immediate recall of words and word re-recognition, and consists of 11 questions out of a possible 70 points, with the higher the score the more cognitively impaired.

Secondary Outcomes

  • Montreal Cognitive Assessment (MoCA)(Baseline and 2 weeks)
  • Digital Span Test; Forward and Backward (DST)(Baseline and 2 weeks)
  • Hamilton Anxiety Scale (HAMA)(Baseline and 2 weeks)
  • Neuropsychiatric Inventory (NPI)(Baseline and 2 weeks)
  • EEG(Baseline and 2 weeks)
  • Logic Memory Test (LMT)(Baseline and 2 weeks)
  • EEG(Baseline and 2 weeks)
  • Mini Mental State Examination (MMSE)(Baseline and 2 weeks)
  • Montreal Cognitive Assessment (MoCA)(Baseline and 2 weeks)
  • Digital Span Test; Forward and Backward (DST)(Baseline and 2 weeks)
  • Hamilton Depression Scale (HAMD)(Baseline and 2 weeks)
  • Hamilton Anxiety Scale (HAMA)(Baseline and 2 weeks)
  • Neuropsychiatric Inventory (NPI)(Baseline and 2 weeks)
  • Judgment of line Judgment of line orientation test (JLOT)(Baseline and 2 weeks)
  • Hooper visual organization test (HVOT)(Baseline and 2 weeks)
  • The Stroop color word test(Baseline and 2 weeks)
  • Logic Memory Test (LMT)(Baseline and 2 weeks)
  • Pittsburgh Sleep Quality Index (PSQI)(Baseline and 2 weeks)

Investigators

Sponsor
Anhui Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

WANG KAI

Director of medical psychological department, Anhui Medical University

Anhui Medical University

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Examination of physical and psychological disease burden in Long/Post-COVID syndrome and chronic respiratory disease - a comparison of patients in need of inpatient rehabilitatioPost-COVID-19 syndromeAsthmaChronic obstructive pulmonary disease (COPD)
DRKS00029236Institut für Allgemeinmedizin und Versorgungsforschung, Technische Universität München400
Recruiting
Not Applicable
Bacillus coagulans MTCC 5856 in management of acute diarrhea in childrenacute diarrhea in children
CTRI/2022/06/043239Sami Sabinsa Group Limited110
Active, not recruiting
Phase 1
Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-KetamiIntrathecal S(+)-ketamine is a potent option in the treatment of chronic severe neuropathic pain in cancer patients refractory to conventional therapeutic strategies (Benrath et al. 2005). However, the lack of systematic safety data limit the neuraxial administration of S(+)-ketamine.Benrath J, Scharbert G, Gustorff B, Adams HA, Kress HG. Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain. Br J Anaesth 200595:247-9.
EUCTR2006-000767-28-ATVienna Medical University
Recruiting
Not Applicable
Consistent musculoskeletal examination and health management using &quot;Health Handbook&quot; in elementary, junior high and high schoolsmusculoskeletal problems
JPRN-UMIN000041072niversity of Tsukuba5,000
Completed
Not Applicable
PressUre uLCers: Effectiveness of Risk assessment tools. A randomised controlled trial (the ULCER Trial)Pressure ulcersSkin - Dermatological conditions
ACTRN12608000541303Joan Webster1,070